Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase III BOLD study of odevixibat in biliary atresia enrolls first patient

July 15, 2020

First patient dosed in phase I study of NX-13

July 15, 2020

Suzhou Kintor and Applied Biology to evaluate proxalutamide in COVID-19 study

July 15, 2020

New activin receptor type-1 inhibitors identified at Incyte

July 15, 2020

Celgene discovers androgen receptor degradation inducers

July 15, 2020

TOLREMO therapeutics patents compounds targeting CREBBP and p300 HAT

July 15, 2020

Apolipoprotein L1 inhibitors discovered at Vertex Pharmaceuticals

July 15, 2020

Acurx Pharmaceuticals describes new bacterial DNA polymerase IIIC inhibitors

July 15, 2020

PC3X as a novel diagnostic and prognostic marker in HCC

July 15, 2020

BPI-23314 shows promising activity in xenograft models of hematological malignancies

July 15, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...